French Language Validation of the 5-minutes Montreal Cognitive Assessment (MoCA)

University Hospital, Lille236 enrolled

Overview

The aim of the study is to validate a french version of the 5 minutes version of the Montreal Cognitive Assessment as compared to the french full version of this test.

The Montreal Cognitive Assessment (MOCA) is a test used to detect cognitive impairments. This test is available in different languages including french. A short version (the 5 minutes MOCA) has also been validated through a phone call use that allows to develop some epidemiological approaches. Nevertheless, this short version has not been validated in french. The main aim of the study is to validate the french translation of the short version of the MOCA as compared the the full french version of the test. To validate the short version, several groups of subjects will be included : healthy subjects, Alzheimer disease patients, Parkinson or Huntington diseases patients as well as diabetic patients. The inclusion of both healthy subjects and patients with different types of cognitive impairments will allow to validate the short version of the test. All subjects and patients will first be submitted to the full version of the MOCA during a face to face procedure. Thirty to forty days later, they will be submitted to the short version of the test through a phone call performed by an independent rater. Subgroups of healthy subjects and patients will also be used to determine the test-retest and inter-rater reliability of the short version of the MOCA.

Study Type

INTERVENTIONAL

Allocation

NON_RANDOMIZED

Purpose

DIAGNOSTIC

Masking

NONE

Enrollment

236

Conditions

Cognitive Symptom Evaluations, Diagnostic Self

Interventions

Full version of the Montreal Cognitive AssessmentDIAGNOSTIC_TEST

Patients or subjects will be submitted to the full version of the MOCA

5 minutes version of the Montreal Cognitive AssessmentDIAGNOSTIC_TEST

The same patients and subjects will be submitted to the 5 minutes version of the MOCA through a phone call

Eligibility

Sex: ALLMin age: 40 YearsMax age: 89 YearsHealthy volunteers:

Medical Language ↔ Plain English

Inclusion Criteria: Healthy Volunteers * Volunteers, BMI \<26 * free from neurological, psychiatric, metabolic or cardiac pathologies; * Absence of active metabolic or cardiac diseases, unstabilized under treatment * Pregnant test negative Patients * Patients suffering from pathologies that may be accompanied by cognitive decline or dementia (Alzheimer's disease, Parkinson's and Huntington's disease, diabetes) that meet the usual diagnostic criteria for these diseases; * Patients should not start treatment of a new therapeutic class under test Exclusion Criteria: * Pregnant or nursing women. * Illiterate subjects * Presence of uncorrected visual or auditory disturbances * "Alcohol use disorder" observed at the Mini International Neuropsychiatric Inventory (MINI); * "Substance use disorder" observed at the MINI; * Participation in a therapeutic trial or in an exclusion period from a previous clinical trial; * Patient whose physical or mental condition does not allow them to pass the study tests; * Persons under guardianship or under trusteeship; * Recent cognitive assessment (less than 6 months) by the classic MoCA

Locations (1)

University Hospital

Lille, France

Outcomes

Primary Outcomes

Correlation between scores obtained with the different versions of the MOCA

To measure the correlation between the results obtained at the short and full versions of the MOCA

Time frame: 30 to 40 days

Secondary Outcomes

Performance of the short version of the MOCA

Receiver operator characteristic (ROC) analyses of the short version of MOCA to determine cognitive impairment as compared to full version as a gold-standard

Time frame: 30 to 40 days

Test-retest reliability

To determine the test-retest reliability of the short version of the MOCA

Time frame: 30 to 40 days

Inter-rater reliability

To determine the inter-rater reliability of the short version of the MOCA

Time frame: 30 to 40 days

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.